What will Expedition Therapeutics use the $115M Series B for?

Expedition says the financing will advance EXPD-101 through Phase 2 development, expand its pipeline of therapies for inflammatory diseases, and strengthen research discovery. The immediate operating priority is the company's global Phase 2 COPD trial.

EXPD-101 is an investigational, once-daily oral DPP1 inhibitor designed to reduce activation of neutrophil serine proteases and address neutrophilic inflammation in COPD. It is not an approved therapy, and Phase 2 must establish whether the mechanism produces meaningful patient outcomes.

How is Expedition's Phase 2 COPD trial designed?

ClinicalTrials.gov record NCT07684820 describes a randomized, double-blind, placebo-controlled study of two EXPD-101 doses given once daily for 52 weeks. The study is expected to enroll 600 adults with COPD.

How much disclosed capital has Expedition Therapeutics raised in its Series A and B?

Expedition announced a $165M Series A in October 2025 and a $115M Series B in August 2026, totaling $280M across those two disclosed rounds. The company also had an earlier seed financing whose amount was not publicly disclosed.

Expedition Therapeutics Raises $115M Series B for COPD Trial

Expedition Therapeutics raised an oversubscribed $115M Series B led by General Atlantic, with RA Capital, Vivo Capital, and the company's existing investors participating. The financing was announced on August 5, 2026, alongside a more consequential operating milestone: the first patient was dosed in Expedition's global Phase 2 study of EXPD-101 for chronic obstructive pulmonary disease.

The paired announcements matter because Expedition is no longer raising against a licensing thesis or preclinical promise. It is financing a randomized, year-long study expected to enroll 600 people. That does not prove EXPD-101 will work, but it moves the company's story into a harder and more useful chapter where trial design, enrollment, safety, retention, and data quality will determine what the molecule is worth.

What Happened

General Atlantic led the Series B, while RA Capital and Vivo Capital joined existing backers Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, joined Expedition's board in connection with the financing.

Expedition said the capital will advance EXPD-101 through Phase 2 clinical development, expand its pipeline of next-generation therapies for inflammatory diseases, and strengthen research discovery. Those are broad ambitions, but the immediate task is specific: execute a large COPD study around a mechanism intended to address neutrophilic inflammation rather than simply manage symptoms downstream.

Why the Phase 2 Milestone Matters

The registered Phase 2 trial is randomized, double-blind, and placebo-controlled. It evaluates two doses of EXPD-101 given orally once daily for 52 weeks, with an estimated enrollment of 600 adults with COPD. The design creates a test of efficacy, safety, tolerability, and pharmacokinetics across a patient population already receiving standard inhaled therapy.

In biotech, first-patient dosing is not a ceremonial ribbon cutting. It means the protocol, sites, drug supply, investigators, screening process, and operating infrastructure have begun functioning as one system. Expedition still faces the ordinary brutality of clinical execution, but the company has crossed from planning a study to running one. That is the difference between owning a development narrative and producing evidence.

How EXPD-101 Fits the COPD Market

EXPD-101 is an investigational, once-daily oral inhibitor of dipeptidyl peptidase 1, or DPP1. Expedition says the molecule is designed to selectively block activation of neutrophil serine proteases, enzymes involved in airway damage and disease progression. The aim is to address neutrophilic inflammation, an important disease mechanism in COPD that is not adequately controlled for many patients by existing treatments.

The company has reported that Phase 1 studies showed tolerability, target engagement, and dose-proportional pharmacokinetics supporting once-daily dosing. Those findings support continued development, but they should not be confused with evidence that the therapy improves patient outcomes. Phase 2 is where Expedition begins asking that more demanding question at a scale large enough to matter.

Expedition acquired exclusive worldwide rights to EXPD-101 from Fosun Pharma in August 2025, excluding mainland China, Hong Kong, and Macau. Fosun is separately advancing the molecule in a Phase 2 bronchiectasis study in China. The licensing structure gave Expedition a clinical-stage asset and a global development opportunity, along with the obligation to prove the program can translate across diseases and geographies.

Capital Built for Clinical Execution

The Series B follows Expedition's $165M Series A announced in October 2025. Together, the two disclosed rounds total $280M, excluding an earlier seed financing whose amount was not disclosed. That is a substantial capital base for a company that emerged publicly in 2025, reflecting both the cost of respiratory drug development and the scale of the opportunity investors believe may exist.

The syndicate also tells a story. General Atlantic adds a large global growth platform and life-sciences leadership, while RA Capital, Vivo Capital, Sofinnova, Novo Holdings, Forbion, Sanofi Ventures, BVF, and Venrock bring specialist healthcare investing experience. A crowded cap table is not clinical validation, but a syndicate with repeat biotechnology experience can help a company absorb the financing, governance, and strategic demands that arrive as trials grow larger.

Leadership at the Inflection Point

Yi Larson, founder, President, and CEO, has worked across biotechnology finance, corporate strategy, and transactions. Expedition's management team also includes Geoff Gilmartin, M.D., as CMO and Eric Hu, Ph.D., as Chief Business Officer. Their jobs now converge around a single operating test: move EXPD-101 through a disciplined Phase 2 program while building enough pipeline depth to avoid becoming a one-asset story by default.

Brett Zbar's addition to the board puts the lead investor closer to that execution. A new director does not change the science, but the appointment tightens alignment between capital, governance, and clinical development as the cost and complexity of the program rise.

What This Signals

Expedition's financing fits a more selective biotechnology market in which capital can still move aggressively toward programs with defined mechanisms, credible operators, and near-term clinical milestones. Investors are not underwriting a finished answer. They are underwriting a structured experiment and the team responsible for producing a trustworthy one.

For founders and operators, capital works best when it is attached to a specific transition that everyone can see and measure. Expedition raised its Series B as EXPD-101 entered a 600-person Phase 2 study, giving the round a clear purpose beyond extending runway or enlarging a pipeline slide.

What to Watch Next

The next meaningful signals will come from trial execution rather than additional adjectives. Enrollment pace, site activation, participant retention, safety observations, dose performance, and eventual clinical outcomes will determine whether EXPD-101's mechanism can translate into a differentiated COPD therapy.

Expedition has assembled the money and people required to attempt that work. Now the company has to produce evidence strong enough to justify the confidence behind $280M in disclosed Series A and B capital. That is a far less comfortable story than a financing announcement, and a far more important one.